IHC analyses demonstrated a similar staining pattern in FFPE prostate tissue adenocarcinoma specimens for fuc-PSA (assessed with anti-fuc-PSA mAb 2E9) and total PSA (assessed with the commercially available mAb, ER-PR8, Roche), with slightly weaker staining intensity and less coverage for fuc-PSA (Supplementary Fig. 5). This evidence concerns the gene KLK3 and medical procedure.